Craft
AnaptysBio

AnaptysBio

Revenue

$63.2 M

FY, 2021

Market Capitalization

$695 M

2022-09-20

AnaptysBio Summary

Company summary

Overview
AnaptysBio is a biotechnology company developing immunology therapeutic product candidates. It focuses on immune control mechanisms applicable to inflammation and immuno-oncology indications. The company offers ANB019, ANB030, and ANB032 antibody programs to address inflammatory disorders.
Type
Public
Founded
2005
HQ
San Diego, CA, US | view all locations
Website
https://www.anaptysbio.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Hamza Suria

    Hamza Suria, President and CEO, Director

    • Paul F. Lizzul

      Paul F. Lizzul, Chief Medical Officer

      • Eric Loumeau

        Eric Loumeau, Chief Operating Officer

        • Beth Mueller

          Beth Mueller, Senior Vice President, Human Resources

          LocationsView all

          2 locations detected

          • San Diego, CA HQ

            United States

            10770 Wateridge Cir Ste. 210

          • San Diego, CA

            United States

            10421 Pacific Center Ct #200

          AnaptysBio Financials

          Summary financials

          Revenue (Q2, 2022)
          $1.2M
          Net income (Q2, 2022)
          ($32.6M)
          Cash (Q2, 2022)
          $71.7M
          EBIT (Q2, 2022)
          ($27.8M)
          Enterprise value
          $643.5M

          Footer menu